医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Fabrinet to Announce Fourth Quarter and Fiscal-Year 2021 Financial Results on August 16, 2021

2021年08月02日 PM09:30
このエントリーをはてなブックマークに追加


 

BANGKOK

Fabrinet (NYSE: FN), a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, today announced it will release its fourth quarter and fiscal-year 2021 financial results for the period ended June 25, 2021 after market close on Monday, August 16, 2021. On that day, management will hold a conference call and webcast at 5:00 p.m. ET to review and discuss the Company’s results.

What:   Fabrinet Fourth Quarter and Fiscal-Year 2021 Financial Results Call
When:   Monday, August 16, 2021
Time:   5:00 p.m. ET
Live Call:   (888) 357-3694, domestic
  (253) 237-1137, international
  Passcode: 2199846
Replay:   (855) 859-2056, domestic
  (404) 537-3406, international
  Passcode: 2199846
Webcast:   https://investor.fabrinet.com/ (live and replay)

A recorded version of this webcast will be available approximately two hours after the call and accessible at https://investor.fabrinet.com/. The webcast will be archived on Fabrinet’s website for a period of one year.

About Fabrinet

Fabrinet is a leading provider of advanced optical packaging and precision optical, electro-mechanical, and electronic manufacturing services to original equipment manufacturers of complex products, such as optical communication components, modules and subsystems, automotive components, medical devices, industrial lasers and sensors. Fabrinet offers a broad range of advanced optical and electro-mechanical capabilities across the entire manufacturing process, including process design and engineering, supply chain management, manufacturing, advanced packaging, integration, final assembly and testing. Fabrinet focuses on production of high complexity products in any mix and any volume. Fabrinet maintains engineering and manufacturing resources and facilities in Thailand, the United States of America, the People’s Republic of China, Israel and the United Kingdom. For more information visit: www.fabrinet.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210802005156/en/

CONTACT

Investor Contact:

Garo Toomajanian

ir@fabrinet.com

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  •  Celltrion’s monoclonal antibody treatment for COVID-19, regdanvimab (CT-P59) becomes the first authorized COVID-19 treatment approved from the Korean Ministry of Food and Drug Safety (MFDS)
  • ENHERTU® Reduced the Risk of Disease Progression or Death by 72% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer
  • ENHERTU® Demonstrated Clinically Meaningful and Durable Response in Patients with HER2 Positive Advanced Gastric Cancer in DESTINY-Gastric02 Phase 2 Trial
  • 武田的EXKIVITY™ (mobocertinib)成为美国FDA首次核准的专为EGFR外显子20插入+ NSCLC患者设计的口服治疗药物
  • Masimo上市单例患者使用的rainbow® SuperSensor™